{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:08:29Z","timestamp":1791396509434,"version":"4.3.3"},"reference-count":41,"publisher":"BMJ","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s40425-017-0301-y","type":"journal-article","created":{"date-parts":[[2017,12,6]],"date-time":"2017-12-06T01:12:56Z","timestamp":1512522776000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":126,"title":["Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials"],"prefix":"10.1136","volume":"5","author":[{"given":"Roman","family":"Groisberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amini","family":"Behrang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Janku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarina","family":"Piha-Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aung","family":"Naing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqing","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Benjamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreyaskumar","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeta","family":"Somaiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Conley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Funda","family":"Meric-Bernstam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6064-6837","authenticated-orcid":false,"given":"Vivek","family":"Subbiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,12,19]]},"reference":[{"issue":"1","key":"301_CR1","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/2159-8274.CD-10-0010","volume":"1","author":"ES Kim","year":"2011","unstructured":"Kim ES, Herbst RS, Wistuba II, et al. The BATTLE Trial: Personalizing Therapy for Lung Cancer. Cancer Discov. 2011;1(1):44\u201353.","journal-title":"Cancer Discov"},{"key":"301_CR2","first-page":"154","volume":"26","author":"EF McCarthy","year":"2006","unstructured":"McCarthy EF. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J. 2006;26:154\u20138.","journal-title":"Iowa Orthop J"},{"issue":"8","key":"301_CR3","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1038\/mt.2016.86","volume":"24","author":"M Ghisoli","year":"2016","unstructured":"Ghisoli M, Barve M, Mennel R, et al. Three-year follow up of GMCSF\/bi-shRNAfurin DNA-transfected Autologous tumor immunotherapy (vigil) in metastatic advanced Ewing's sarcoma. Mol Ther. 2016;24(8):1478\u201383.","journal-title":"Mol Ther"},{"key":"301_CR4","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13045-016-0278-x","volume":"9","author":"GJB McCaughan","year":"2016","unstructured":"McCaughan GJB, Fulham MJ, Mahar A, et al. Programmed cell death-1 blockade in recurrent disseminated Ewing sarcoma. J Hematol Oncol. 2016;9:48.","journal-title":"J Hematol Oncol"},{"key":"301_CR5","doi-asserted-by":"crossref","unstructured":"Miwa S, Nishida H, Tanzawa Y, et al. Phase 1\/2 study of immunotherapy with dendritic cells pulsed with autologous tumor lysate in patients with refractory bone and soft tissue sarcoma. Cancer. 2017:n\/a-n\/a.","DOI":"10.1002\/cncr.30606"},{"issue":"3","key":"301_CR6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2165\/11204910-000000000-00000","volume":"12","author":"JE Frampton","year":"2010","unstructured":"Frampton JE. Mifamurtide: A Review of its Use in the Treatment of Osteosarcoma. Pediatr-Drugs. 2010;12(3):141\u201353.","journal-title":"Pediatr-Drugs"},{"issue":"8","key":"301_CR7","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.1992.10.8.1310","volume":"10","author":"ES Kleinerman","year":"1992","unstructured":"Kleinerman ES, Jia SF, Griffin J, Seibel NL, Benjamin RS, Jaffe N. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. J Clin Oncol. 1992;10(8):1310\u20136.","journal-title":"J Clin Oncol"},{"issue":"2","key":"301_CR8","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/sj.bjc.6601074","volume":"89","author":"KJ Roozendaal","year":"2003","unstructured":"Roozendaal KJ, de Valk B, ten Velden JJA, van der Woude HJ, Kroon BBR. Alveolar soft-part sarcoma responding to interferon alpha-2b. Br J Cancer. 2003;89(2):243\u20135.","journal-title":"Br J Cancer"},{"issue":"1","key":"301_CR9","doi-asserted-by":"crossref","first-page":"e14611","DOI":"10.1371\/journal.pone.0014611","volume":"6","author":"SW Sorbye","year":"2011","unstructured":"Sorbye SW, Kilvaer T, Valkov A, et al. Prognostic impact of lymphocytes in soft tissue sarcomas. PLoS One. 2011;6(1):e14611.","journal-title":"PLoS One"},{"issue":"10","key":"301_CR10","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1002\/ijc.28581","volume":"134","author":"H Fujii","year":"2014","unstructured":"Fujii H, Arakawa A, Utsumi D, et al. CD8+tumor-infiltrating lymphocytes at primary sites as a possible prognostic factor of cutaneous angiosarcoma. Int J Cancer. 2014;134(10):2393\u2013402.","journal-title":"Int J Cancer"},{"issue":"12","key":"301_CR11","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1158\/0008-5472.CAN-13-0371","volume":"73","author":"S Rusakiewicz","year":"2013","unstructured":"Rusakiewicz S, Semeraro M, Sarabi M, et al. Immune infiltrates are prognostic factors in localized gastrointestinal Stromal tumors. Cancer Res. 2013;73(12):3499\u2013510.","journal-title":"Cancer Res"},{"issue":"2","key":"301_CR12","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1158\/1078-0432.CCR-16-1163","volume":"23","author":"AM Seifert","year":"2017","unstructured":"Seifert AM, Zeng S, Zhang JQ, et al. PD-1\/PD-L1 blockade enhances T-cell activity and antitumor efficacy of Imatinib in gastrointestinal Stromal tumors. Clin Cancer Res. 2017;23(2):454\u201365.","journal-title":"Clin Cancer Res"},{"issue":"19","key":"301_CR13","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer. N Engl J Med. 2016;375(19):1823\u201333.","journal-title":"N Engl J Med"},{"issue":"3","key":"301_CR14","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.humpath.2014.11.001","volume":"46","author":"SP D\u2019Angelo","year":"2015","unstructured":"D\u2019Angelo SP, Shoushtari AN, Agaram NP, et al. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Hum Pathol. 2015;46(3):357\u201365.","journal-title":"Hum Pathol"},{"issue":"9","key":"301_CR15","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/modpathol.2016.108","volume":"29","author":"M Kostine","year":"2016","unstructured":"Kostine M, Cleven AH, de Miranda NF, Italiano A, Cleton-Jansen AM, Bovee JV. Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype. Mod Pathol. 2016;29(9):1028\u201337.","journal-title":"Mod Pathol"},{"key":"301_CR16","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1186\/s12885-016-2451-6","volume":"16","author":"C Kim","year":"2016","unstructured":"Kim C, Kim EK, Jung H, et al. Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. BMC Cancer. 2016;16:434.","journal-title":"BMC Cancer"},{"issue":"12","key":"301_CR17","doi-asserted-by":"crossref","first-page":"e82870","DOI":"10.1371\/journal.pone.0082870","volume":"8","author":"JR Kim","year":"2013","unstructured":"Kim JR, Moon YJ, Kwon KS, et al. Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS One. 2013;8(12):e82870.","journal-title":"PLoS One"},{"key":"301_CR18","unstructured":"Raj S, Bui R, Gonzales D, Letson SJ. Impact of PDL1 expression on clinical outcomes in subtypes of sarcoma. 2014\/09\/27\/, 2014."},{"key":"301_CR19","doi-asserted-by":"crossref","unstructured":"George S, Barysauskas CM, Solomon S, et al. Phase 2 study of nivolumab in metastatic leiomyosarcoma of the uterus. Journal of Clinical Oncology. 2016;34(suppl; abstr 11007).","DOI":"10.1200\/JCO.2016.34.15_suppl.11007"},{"key":"301_CR20","doi-asserted-by":"crossref","first-page":"39254","DOI":"10.18632\/oncotarget.16845","volume":"5","author":"R Groisberg","year":"2017","unstructured":"Groisberg R, Hong DS, Holla V, et al. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. Oncotarget. 2017;5:39254\u201367.","journal-title":"Oncotarget"},{"key":"301_CR21","doi-asserted-by":"crossref","unstructured":"Paoluzzi L, Cacavio A, Ghesani M, et al. Response to anti-PD1 therapy with nivolumab in metastatic sarcomas. Clin Sarcoma Res. 2016;6","DOI":"10.1186\/s13569-016-0064-0"},{"key":"301_CR22","doi-asserted-by":"crossref","unstructured":"Tawbi HA-H, Burgess MA, Crowley J, et al. Safety and efficacy of PD-1 blockade using pembrolizumab in patients with advanced soft tissue (STS) and bone sarcomas (BS): Results of SARC028\u2014A multicenter phase II study. Journal of Clinical Oncology. 2016;34(suppl; abstr 11006).","DOI":"10.1200\/JCO.2016.34.15_suppl.11006"},{"key":"301_CR23","unstructured":"Wilky B. Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas. 2015 - Full Text View - ClinicalTrials.gov ."},{"key":"301_CR24","doi-asserted-by":"crossref","unstructured":"Subbiah V, Meyer C, Zinner R, et al. Phase Ib\/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma. Clin Cancer Res. 2017;17:0272.","DOI":"10.1158\/1078-0432.CCR-17-0272"},{"issue":"6","key":"301_CR25","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1159\/000449204","volume":"91","author":"V Subbiah","year":"2016","unstructured":"Subbiah V, Holmes O, Gowen K, et al. Activity of c-met\/ALK inhibitor Crizotinib and multi-Kinase VEGF inhibitor Pazopanib in metastatic gastrointestinal Neuroectodermal tumor harboring EWSR1-CREB1 fusion. Oncology. 2016;91(6):348\u201353.","journal-title":"Oncology"},{"issue":"4","key":"301_CR26","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/CCO.0b013e3283477a94","volume":"23","author":"V Subbiah","year":"2011","unstructured":"Subbiah V, Kurzrock R. Phase 1 clinical trials for sarcomas: the cutting edge. Curr Opin Oncol. 2011;23(4):352\u201360.","journal-title":"Curr Opin Oncol"},{"issue":"11","key":"301_CR27","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1136\/jcp.2005.031120","volume":"59","author":"AL Folpe","year":"2006","unstructured":"Folpe AL, Deyrup AT. Alveolar soft-part sarcoma: a review and update. J Clin Pathol. 2006;59(11):1127\u201332.","journal-title":"J Clin Pathol"},{"issue":"4","key":"301_CR28","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1158\/0008-5472.CAN-16-2486","volume":"77","author":"M Tanaka","year":"2017","unstructured":"Tanaka M, Homme M, Yamazaki Y, Shimizu R, Takazawa Y, Nakamura T. Modeling alveolar soft part sarcoma unveils novel mechanisms of metastasis. Cancer Res. 2017;77(4):897\u2013907.","journal-title":"Cancer Res"},{"issue":"1","key":"301_CR29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/intimm\/dxu079","volume":"27","author":"O Yoshie","year":"2015","unstructured":"Yoshie O, Matsushima K. CCR4 and its ligands: from bench to bedside. Int Immunol. 2015;27(1):11\u201320.","journal-title":"Int Immunol"},{"key":"301_CR30","doi-asserted-by":"crossref","unstructured":"Conley AP, Trinh VA, Zobniw CM, et al. Positive Tumor Response to Combined Checkpoint Inhibitors in a Patient With Refractory Alveolar Soft Part Sarcoma: A Case Report. JGO. 2017:JGO.2017.009993.","DOI":"10.1200\/JGO.2017.009993"},{"key":"301_CR31","doi-asserted-by":"crossref","unstructured":"Samer Salah JHL, Scott Davidson, Nathaniel Anderson, Sergio L Periera, Beatrice Lau, Adam Shlien, Brendan Dickson, Peter Ferguson, Jay Wunder, Albiruni Ryan Abdul Razak. Immunoprofiling in alveolar soft part sarcoma. J Clin Oncol 35, 2017 (suppl; abstr 11059). 2017.","DOI":"10.1200\/JCO.2017.35.15_suppl.11059"},{"key":"301_CR32","unstructured":"Burgess MA. Multicenter phase II study of pembrolizumab (P) in advanced soft tissue (STS) and bone sarcomas (BS): Final results of SARC028 and biomarker analyses. Paper presented at: ASCO 2017; 2017\/06\/02\/, 2017."},{"key":"301_CR33","doi-asserted-by":"crossref","unstructured":"Toulmonde M, Penel N, Adam J, et al. Use of pd-1 targeting, macrophage infiltration, and ido pathway activation in sarcomas: a phase 2 clinical trial. JAMA Oncol. 2017;","DOI":"10.1001\/jamaoncol.2017.1617"},{"issue":"9","key":"301_CR34","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/nm.2438","volume":"17","author":"VP Balachandran","year":"2011","unstructured":"Balachandran VP, Cavnar MJ, Zeng S, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med. 2011;17(9):1094\u2013100.","journal-title":"Nat Med"},{"key":"301_CR35","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40425-017-0238-1","volume":"5","author":"MJ Reilley","year":"2017","unstructured":"Reilley MJ, Bailey A, Subbiah V, et al. Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. J Immunother Cancer. 2017;5:35.","journal-title":"J Immunother Cancer"},{"issue":"12","key":"301_CR36","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1182\/blood-2014-09-600924","volume":"125","author":"M Duvic","year":"2015","unstructured":"Duvic M, Pinter-Brown LC, Foss FM, et al. Phase 1\/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood. 2015;125(12):1883\u20139.","journal-title":"Blood"},{"issue":"5","key":"301_CR37","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1002\/cncr.26413","volume":"118","author":"I Garrido-Laguna","year":"2012","unstructured":"Garrido-Laguna I, Janku F, Vaklavas C, et al. Validation of the Royal Marsden Hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center. Cancer. 2012;118(5):1422\u20138.","journal-title":"Cancer"},{"key":"301_CR38","doi-asserted-by":"crossref","first-page":"35448","DOI":"10.1038\/srep35448","volume":"6","author":"V Subbiah","year":"2016","unstructured":"Subbiah V, Hess KR, Khawaja MR, et al. Evaluation of novel targeted therapies in aggressive biology sarcoma patients after progression from US FDA approved therapies. Sci Rep. 2016;6:35448.","journal-title":"Sci Rep"},{"issue":"39","key":"301_CR39","doi-asserted-by":"crossref","first-page":"64421","DOI":"10.18632\/oncotarget.10910","volume":"7","author":"JA Livingston","year":"2016","unstructured":"Livingston JA, Hess KR, Naing A, et al. Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials. Oncotarget. 2016;7(39):64421\u201330.","journal-title":"Oncotarget"},{"issue":"8","key":"301_CR40","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1158\/1078-0432.CCR-16-1741","volume":"23","author":"S Champiat","year":"2017","unstructured":"Champiat S, Dercle L, Ammari S, et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1\/PD-L1. Clin. Cancer Res. 2017;23(8):1920\u20138.","journal-title":"Clin. Cancer Res."},{"issue":"15","key":"301_CR41","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1158\/1078-0432.CCR-16-3133","volume":"23","author":"S Kato","year":"2017","unstructured":"Kato S, Goodman AM, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R. Hyper-progressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res. 2017;23(15):4242\u201350.","journal-title":"Clin Cancer Res"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-017-0301-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T23:09:23Z","timestamp":1660086563000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-017-0301-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["301"],"URL":"https:\/\/doi.org\/10.1186\/s40425-017-0301-y","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12]]},"article-number":"100"}}